The emerging target KRAS G12C in genitourinary malignancies

被引：0
|
作者：
Grivas, Petros
Necchi, Andrea
Bratslavsky, Gennady
Shapiro, Oleg
Jacob, Joseph
Elvin, Julia Andrea
Vergilio, Jo-Anne
Killian, Keith
Williams, Erik
Ramkissoon, Shakti H.
Severson, Eric Allan
Hemmerich, Amanda
Schrock, Alexa Betzig
Chung, Jon
McGregor, Kimberly
Reddy, Prasanth
Alexander, Brian Michael
Sokol, Ethan
Danziger, Natalie
Ross, Jeffrey S.
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA
[4] SUNY Upstate Med Univ, Syracuse, NY 13210 USA
[5] Fdn Med Inc, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
434
引用
收藏
页数：3
相关论文
共 50 条
  • [1] LANDSCAPE OF KRAS G12C MUTATIONS IN GENITOURINARY MALIGNANCIES
    Rebecca, Sager A.
    Michael, Basin F.
    Hanan, Goldberg
    Jeffrey, Ross S.
    Gennady, Bratslavsky
    Joseph, Jacob M.
    Petros, Grivas
    Andrea, Necchi
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S69 - S69
  • [2] The Emerging Anti-Cancer Target KRAS G12C: A Pangenomic Study
    Ross, Jeffrey
    Sokol, Ethan
    Madison, Russell
    Chung, Jon
    Miller, Vincent
    Ali, Siraj
    Elvin, Julia
    Vergilio, Jo-Anne
    Killian, Keith
    Lin, Douglas
    Williams, Erik
    Danziger, Natalie
    Haberberger, James
    Tse, Julie
    Ramkissoon, Shakti
    Severson, Eric
    Hemmerich, Amanda
    Ferguson, Naomi Lynn
    Edgerly, Claire
    Duncan, Daniel
    Huang, Richard
    Schrock, Alexa
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 1709 - 1710
  • [3] The Emerging Anti-Cancer Target KRAS G12C: A Pangenomic Study
    Ross, Jeffrey
    Sokol, Ethan
    Madison, Russell
    Chung, Jon
    Miller, Vincent
    Ali, Siraj
    Elvin, Julia
    Vergilio, Jo-Anne
    Killian, Keith
    Lin, Douglas
    Williams, Erik
    Danziger, Natalie
    Haberberger, James
    Tse, Julie
    Ramkissoon, Shakti
    Severson, Eric
    Hemmerich, Amanda
    Ferguson, Naomi Lynn
    Edgerly, Claire
    Duncan, Daniel
    Huang, Richard
    Schrock, Alexa
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 1709 - 1710
  • [4] Two new agents target KRAS G12C
    Diana Romero
    Nature Reviews Clinical Oncology, 2020, 17 (1) : 6 - 6
  • [5] Two new agents target KRAS G12C
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2020, 17 (01) : 6 - 6
  • [6] KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population
    Schirripa, Marta
    Nappo, Floriana
    Cremolini, Chiara
    Salvatore, Lisa
    Rossini, Daniele
    Bensi, Maria
    Businello, Gianluca
    Pietrantonio, Filippo
    Randon, Giovanni
    Fuca, Giovanni
    Boccaccino, Alessandra
    Bergamo, Francesca
    Lonardi, Sara
    Dei Tos, Angelo Paolo
    Fassan, Matteo
    Loupakis, Fotios
    CLINICAL COLORECTAL CANCER, 2020, 19 (03) : 219 - 225
  • [7] KRAS G12C Mutations in NSCLC: From Target to Resistance
    Addeo, Alfredo
    Banna, Giuseppe Luigi
    Friedlaender, Alex
    CANCERS, 2021, 13 (11)
  • [8] G12C KRAS mutant colorectal cancer, optimising the target
    Price, T. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S1300 - S1300
  • [9] Drugging the Undruggable and beyond: Emerging precision oncology approaches to target acquired resistance to KRAS G12C and KRAS G12D inhibitors
    Kale, Ramesh
    Samant, Charudatt
    Nandakumar, Krishnadas
    Pai, K. Sreedhara Ranganath
    Bhonde, Mandar
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2025, 760
  • [10] EMT is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C mutant NSCLC
    Adachi, Yuta
    Ito, Kentaro
    Kimura, Ryo
    Yamaguchi, Rui
    Ebi, Hiromichi
    ANNALS OF ONCOLOGY, 2021, 32 : S307 - S307
12345